A Detailed Analysis of the PCSK9 Inhibitor Market by Alirocumab and Evolocumab Drugs, from 2024 to 2034

<p>Exhibiting a y-o-y growth of 21.5%, the global <strong>PCSK9 inhibitor market</strong> size is estimated to reach US$ 2,733.7 million in 2024. It will likely expand at a CAGR of 18.7% during the forecast period, with total sales of PCSK9 inhibitors reaching US$ 15,140.3 million by 2034.</p><table><tbody><tr><th scope='row'>Attributes</th><td>Key Insights</td></tr><tr><th scope='row'>Base Value (2023)</th><td>US$ 2,250.4 million</td></tr><tr><th scope='row'>Estimated PCSK9 Inhibitor Market Value (2024)</th><td>US$ 2,733.7 million</td></tr><tr><th scope='row'>Projected PCSK9 Inhibitor Market Revenue (2034)</th><td>US$ 15,140.3 million</td></tr><tr><th scope='row'>Value CAGR (2024 to 2034)</th><td>18.7%</td></tr></tbody></table><p>Country-wise Insights</p><table><tbody><tr><th scope='row'>Countries</th><td>Value CAGR</td></tr><tr><th scope='row'>United States</th><td>17.0%</td></tr><tr><th scope='row'>Germany</th><td>13.4%</td></tr><tr><th scope='row'>South Korea</th><td>26.2%</td></tr><tr><th scope='row'>India</th><td>9.4%</td></tr><tr><th scope='row'>Italy</th><td>21.0%</td></tr></tbody></table><p>Category-wise Insights</p><table><tbody><tr><th scope='row'>Drug</th><td>Value CAGR</td></tr><tr><th scope='row'>Alirocumab</th><td>11.3%</td></tr><tr><th scope='row'>Evolocumab</th><td>19.4%</td></tr><tr><th scope='row'>Inclisiran</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>Modality</th><td>Value CAGR</td></tr><tr><th scope='row'>Fully-humanized monoclonal antibodies</th><td>17.9%</td></tr><tr><th scope='row'>siRNA</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>Indication</th><td>Value CAGR</td></tr><tr><th scope='row'>Primary Hyperlipidemia</th><td>20.7%</td></tr><tr><th scope='row'>Familial Hyper Cholesterolemia</th><td>14.6%</td></tr><tr><th scope='row'>Prevention of Other Cardiovascular Events</th><td>24.8%</td></tr></tbody></table>

<p>呈现出年同比增长率21.5%的态势，全球强效PCSK9抑制剂市场预计在2024年将达到27.3亿美元。在预测期内，该市场预计将以18.7%的复合年增长率持续扩张，至2034年，PCSK9抑制剂的总销售额将达到151.4亿美元。</p><table><tbody><tr><th scope='row'>属性</th><td>关键洞察</td></tr><tr><th scope='row'>基础价值（2023年）</th><td>27.5亿美元</td></tr><tr><th scope='row'>预计PCSK9抑制剂市场价值（2024年）</th><td>27.3亿美元</td></tr><tr><th scope='row'>预测PCSK9抑制剂市场收益（2034年）</th><td>151.4亿美元</td></tr><tr><th scope='row'>价值复合年增长率（2024年至2034年）</th><td>18.7%</td></tr></tbody></table><p>按国家洞察</p><table><tbody><tr><th scope='row'>国家</th><td>价值复合年增长率</td></tr><tr><th scope='row'>美国</th><td>17.0%</td></tr><tr><th scope='row'>德国</th><td>13.4%</td></tr><tr><th scope='row'>韩国</th><td>26.2%</td></tr><tr><th scope='row'>印度</th><td>9.4%</td></tr><tr><th scope='row'>意大利</th><td>21.0%</td></tr></tbody></table><p>按类别洞察</p><table><tbody><tr><th scope='row'>药物</th><td>价值复合年增长率</td></tr><tr><th scope='row'>阿利库单</th><td>11.3%</td></tr><tr><th scope='row'>依沃库单</th><td>19.4%</td></tr><tr><th scope='row'>英克利斯兰</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>给药方式</th><td>价值复合年增长率</td></tr><tr><th scope='row'>全人源单克隆抗体</th><td>17.9%</td></tr><tr><th scope='row'>siRNA</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>适应症</th><td>价值复合年增长率</td></tr><tr><th scope='row'>原发性高脂血症</th><td>20.7%</td></tr><tr><th scope='row'>家族性高胆固醇血症</th><td>14.6%</td></tr><tr><th scope='row'>预防其他心血管事件</th><td>24.8%</td></tr></tbody></table>